Cost analysis of SGLT2 inhibitors in patients with type 2 diabetes in India

Background: Millions of people worldwide are affected by diabetes and this disease has increased morbidity, compromised quality of life and also increased mortality. According to World Health Organization (WHO), India had 69.2 million people living with diabetes in 2015. Sodium glucose co-transporte...

Full description

Saved in:
Bibliographic Details
Published inResearch journal of pharmacy and technology Vol. 13; no. 12; pp. 5861 - 5865
Main Authors Sriram, S., Elizabeth, Arul Amutha, Akila, L.
Format Journal Article
LanguageEnglish
Published Raipur A&V Publications 01.12.2020
Subjects
Chronic illnesses
Control algorithms
Cost analysis
Diabetes
Disease
Expenditures
Glucose
Insulin resistance
Mortality
Patients
Pharmaceutical industry
Pharmacy
Prescription drugs
Quality of life
Wage & price controls
India
Online AccessGet full text

Cover

More Information
Summary:Background: Millions of people worldwide are affected by diabetes and this disease has increased morbidity, compromised quality of life and also increased mortality. According to World Health Organization (WHO), India had 69.2 million people living with diabetes in 2015. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a new class of oral anti-diabetic drugs, have garnered considerable attention in the recent past. In the recent AACE and ADA guidelines, SGLT2 inhibitors have moved up the ladder next only to Metformin and GLP-1 Receptor Agonists, in management of Diabetes mellitus. Methods: Prices of various Gliflozins (SGLT2 Inhibitors) marketed by different companies were obtained from pharmacies in the locality. The variation between highest and lowest price of the different molecules manufactured by various pharmaceutical companies and percentage variation in price for ten tablets was calculated. Results: 358.8% is the cost difference between the most expensive and least expensive gliflozin brand available in India. Conclusion: Cost of various molecules available in the market has to be known by the physician and kept in mind before prescribing the particular drug. Benefit to the patient and better drug compliance can be ensured by opting cheaper alternatives without compromising quality of the drug. Wherever needed, dose escalations or combination drugs should be initiated before opting Expensive drugs.
ISSN:0974-3618
0974-360X
0974-306X
DOI:10.5958/0974-360X.2020.01021.5